Clinical Trial

Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data

Study acronym: LivSPECTRUS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to test the performance of neuronal networks trained on ultrasonic raw Data (=radiofrequency data) for the assessment of liver diseases in patients undergoing a clinical ultrasound examination. The general feasibility is currently evaluated in a retrospective cohort. The main questions the study aims to answer are: * Can a neuronal network trained on RF Data perform equally good as elastography in the assessment of diffuse liver diseases? * Can a neuronal network trained on RF Data perform better than a neuronal network trained on b-mode images in the assessment of diffuse liver diseases? * Can a neuronal network trained on RF Data distinguish focal pathologies in the liver from healthy tissue? To answer these questions participants with a clinically indicated fibroscan will undergo: * a clinical elastography in Case ob suspected diffuse liver disease * a reliable ground truth (if normal ultrasound is not sufficient e.g. contrast enhanced ultrasound, biopsy, MRI or CT) in case of focal liver diseases, depending on the standard routine of the participating center * a clinical ultrasound examination during which b-mode images and the corresponding RF-Data sets are captured
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-15; most recent amendment 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2024-08-05
Trial Details
NCT Number NCT06317181
Lead Sponsor Technische Universität Dresden
Collaborators: University Hospital Dresden, University of Leipzig
Conditions Artificial Intelligence, Ultrasonography, Elasticity Imaging Techniques, Liver Diseases, Metastasis to Liver
Enrollment 200 participants
Start Date 2024-04-01
Primary Completion 2025-10 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-20